DexTech Medical AB, Half-year report July 1 - December 31, 2022

Summary of the second quarter (2022-10-01 – 2022-12-31)

• Net sales amounted to MSEK 0,0 (0,0)
• Operating profit/loss amounted to MSEK -1,2 (-1,1)
• Earnings per share* SEK -0.06 (-0.08)

* Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 18,485,857. For the comparison period, the average number of shares was 14,920,478. Amounts in brackets refer to the corresponding period last year.

Summary of the first half-year (2022-07-01 – 2022-12-31)

• Net sales amounted to MSEK 0,0 (0,0)
• Operating profit/loss amounted to MSEK -2,0 (-2,1)
• Earnings per share* SEK -0.11 (-0.14)
• Cash and cash equivalents at the end of the period amounted to MSEK 30,4 (35,5)

* Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 18,485,857. For the comparison period, the average number of shares was 15,366,150. Amounts in brackets refer to the corresponding period last year.

CEO's comment

The application for a clinical phase 1 study regarding OsteoDex treatment of multiple myeloma was approved by the Swedish Medical Products Agency and permission was announced on August 10, 2022. The study will include 20 patients with multiple myeloma and be conducted at approximately 4–5 hospital centers in Sweden and the rest of the Nordic region.

Principal investigator (PI) is Dr Katarina Uttervall, MD, PhD, Division of Hematology/HERM, Karolinska University Hospital, Huddinge. The main blood markers will be analyzed at the Central Laboratory, Karolinska University Hospital, NKS, Solna. The patients included have relapsed/treatment-resistant disease and have received 1–3 prior lines of therapy. The primary objective is to confirm safety and tolerability and as a secondary objective to determine treatment response documented by changes in the level of disease-related biomarkers. Documentation of quality of life will also be done (QoL scores).

Completion of study material (GMP manufactured OsteoDex) is underway at Biovian Turku, Finland, which is the company's CMO. The study is expected to start  in 2023  and is expected to be completed during Q3 2024.

Anders R Holmberg
CEO

Contact

Anders Holmberg, CEO, +46 73 324 27 82

Gösta Lundgren, CFO, +46 70 710 47 88

This information is such information that DexTech Medical AB is required to disclose in accordance with the EU Market Abuse Regulation. The information was submitted for publication on February 15, 2023 through the care of the above contact persons.

DexTech Medical AB is a Swedish research company that, based on its technology platform, has developed four drug candidates that are protected by patents. The main candidate is OsteoDex for the treatment of castration-resistant prostate cancer (CRPC) with bone metastases. A successful clinical phase II study has been conducted with OsteoDex where the results show high tolerability with mild side effects and treatment effect on patients who fail on existing drugs. DexTech's goal is to outlicense each drug candidate no later than after the completed phase II study. DexTech Medical AB is listed on Spotlight Stock Market.